Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 14 Active Ingredients Included in NHI Price List
June 18, 2001
- Takeda Discovers Metastasis Suppressor Peptide Ligand
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
June 18, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIE -1-
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
June 18, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 18, 2001
- Patient-Oriented Healthcare Discussed: JPMA Seminar
June 18, 2001
- REGULATORY NEWS IN BRIEF
June 18, 2001
- Taxol Approved for Gastric Cancer
June 18, 2001
- All Parties Should Cooperate to Establish Desirable Trade Practices: EAD Director
June 18, 2001
- DIAGNOSTIC NEWS IN BRIEF
June 18, 2001
- Drug Safety Measures by Korosho Must Meet Int'l Standards: PMSB
June 18, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
June 11, 2001
- Sankyo's Olmesartan More Effective than Other ARBs: Study
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
June 11, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -3-
June 11, 2001
- Proposed Drug Classification Gives Top Priority to Clinical Usage
June 11, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -4-
June 11, 2001
- Implementation Working Group Formed for Coordinated Application of CTD
June 11, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…